Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis:.a multicenter, retrospective study / Nettis, E., Ferrucci, S.M., Ortoncelli, M., Pellacani, G., Foti, C., Di Leo, E., Patruno, C., Rongioletti, F., Argenziano, G., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Romita, P., Di Bona, D., Nisticò, S.P., Piras, V., Calabrese, G., Detoraki, C., et al.. - In: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY. - ISSN 1018-9068. - 32:2(2022), pp. 124-132. [10.18176/jiaci.0641]
Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis:.a multicenter, retrospective study
Pellacani, G;Nisticò, S P;
2022
Abstract
Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.| File | Dimensione | Formato | |
|---|---|---|---|
|
Nettis_Use-Of-Dupilumab_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
380.64 kB
Formato
Adobe PDF
|
380.64 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
